<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) </plain></SENT>
<SENT sid="1" pm="."><plain>This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucagon secretion, which results in lowering of <z:chebi fb="105" ids="17234">glucose</z:chebi> levels and improvement of the glycemic control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>This review summarizes experiences with DPP-4 inhibition in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, with a focus on <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> has in several clinical studies been shown to improve metabolic control in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, both when used as monotherapy and when used in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> or insulin </plain></SENT>
<SENT sid="4" pm="."><plain>The reduction in HbA(1c) is â‰ˆ 0.6% to 1.0% from baseline levels of 7.5% to 8.7% over 6 to 12 months therapy </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> has a favorable safety profile, is highly tolerable, and there is a minimal risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> is body weight neutral or induces a slight body weight reduction </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> may be used in the early stages of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi> or other treatments in subjects with inadequate glycemic control on these treatments alone </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> may also be used in monotherapy and, finally, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> may be used in combination with insulin in more advanced stages of the disease </plain></SENT>
</text></document>